DALLAS, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest”) (Nasdaq:CSWC), an internally managed business development company focused on providing flexible financing solutions to support the acquisition and growth of middle market businesses, announced today that it supported Ancor Capital Partners’ recent acquisition of STATinMED Research, Inc. (“STATinMED”) with a first lien term loan and an equity co-investment. Capital Southwest led the financing transaction and will act as the sole administrative agent on the credit facility. CION Investment Corporation, Harbert Management Corporation and Dos Rios Partners also invested in the term loan and equity.
"We are pleased to partner with Ancor on its acquisition of STATinMED. Ancor has deep experience in the healthcare sector and we believe their capabilities will enhance STATinMed’s growth opportunities," said Bill Ashbaugh, Managing Director of Capital Southwest. Matt Darrah, Principal of Capital Southwest Corporation said, “Health Economics and Outcomes Research is a rapidly growing sector within pharmaceutical services and STATinMED’s proprietary research methodologies and diverse set of data sources uniquely position STATinMed to continue to deliver a strong value proposition to its blue-chip pharmaceutical company clients. STATinMed’s work product stands at the nexus of the increasingly advanced, rapidly growing and expensive development of new drug therapies and the increasing importance of understanding and proving out value propositions to the payors and patients.”
“We are pleased with the selection of Capital Southwest to lead this financing transaction. Capital Southwest and its partners delivered an attractive financing solution that provided enhanced certainty to close and the flexibility to help STATinMed achieve its growth potential,” said Vic Keller, Managing Partner at Ancor Capital Partners.
Founded in 2007, STATinMED Research is a health economics and outcomes research company that provides research, consulting and targeted communications for global pharmaceutical, biotechnology and health information companies. STATinMED consultants hold extensive academic credentials and bring multidisciplinary academic and industrial expertise in health economics, pharmacoeconomics, clinical or outcomes research, research design, econometrics, statistics and biostatistics. At the core of STATinMED’s mission is the continuing effort to help customers in the health care industry manage costs and improve the quality of care.
About Capital Southwest
Capital Southwest Corporation (Nasdaq: CSWC) is a Dallas, Texas-based, internally managed business development company with approximately $307 million in net assets as of June 30, 2018. Capital Southwest is a middle market lending firm focused on supporting the acquisition and growth of middle market businesses with $5 to $25 million investments across the capital structure, including first lien, unitranche, second lien, subordinated debt and non-control equity co-investments. As a public company with a permanent capital base, Capital Southwest has the flexibility to be creative in its financing solutions and to invest to support the growth of its portfolio companies over long periods of time.
About Ancor Capital Partners
Ancor Capital Partners, a Dallas-based private equity firm, is focused on helping companies reach their next level of growth. Ancor’s experienced team has the acumen, expertise and resources to invest wisely in existing successful companies through private equity buyouts. As a seasoned operating partner, Ancor works to operationally optimize businesses, maximize growth opportunities and instill a lasting culture. With a proven track record of over 50 successful acquisitions to date, Ancor targets health care, consumer staples, industrial manufacturing, automotive and emerging market businesses. For more information, visit www.ancorcapital.com.
Forward-Looking Statements
This press release contains historical information and forward-looking statements with respect to the business and investments of Capital Southwest. Forward-looking statements are statements that are not historical statements and can often be identified by words such as "will," "believe," "expect" and similar expressions and variations or negatives of these words. These statements are based on management's current expectations, assumptions and beliefs. They are not guarantees of future results and are subject to numerous risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statement. These risks include risks related to changes in the markets in which Capital Southwest invests, changes in the financial and lending markets, regulatory changes, tax treatment and general economic and business conditions.
Readers should not place undue reliance on any forward-looking statements and are encouraged to review Capital Southwest's Annual Report on Form 10-K for the year ended March 31, 2018 and subsequent filings with the Securities and Exchange Commission for a more complete discussion of the risks and other factors that could affect any forward-looking statements. Except as required by the federal securities laws, Capital Southwest does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changing circumstances or any other reason after the date of this press release.
Investor Relations Contact:
Michael S. Sarner, Chief Financial Officer
214-884-3829